転移性ホルモン感受性前立腺癌患者における相同組換え修復変異、次世代シーケンシング検査、及び人種による治療進行

Bilen et al. (Thu,) はこの質問を研究した。

www.synapsesocial.com/papers/69a75d7ec6e9836116a2796f — DOI: https://doi.org/10.1016/j.urology.2026.01.024

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer· 2024 · 9 citations
2. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin· 2020 · 487 citations
3. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer· 2023 · 15 citations
4. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial· 2023 · 195 citations
5. Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer· 2023 · 10 citations